Company intelligence / Profile preview

Immetas Therapeutics

East Hanover, New Jersey, United Statesimmetas.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Immetas is developing a pipeline of small molecule and biologic drugs, including bispecific antibodies, aimed at modulating the innate immune system to treat age-related cancers and inflammatory/autoimmune diseases. The company leverages clinical evidence and mechanistic insights into chronic inflammation as a driver of aging and disease. Lead programs are focused on overcoming resistance to conventional immunotherapies by regulating inflammation in the tumor microenvironment. No human clinical results have been reported yet.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesBiologics (including bispecific antibodies)mRNA therapeutics (in collaboration)
Industry: Biotech

Partnerships

GC Biopharma—collaboration on mRNA therapeutics for autoimmune disease

Beyond the preview

Go deeper on Immetas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immetas Therapeutics.

Explore the full profile